Form 4: ResMed Director Carol Burt Awarded 1,073 RSUs

ResMed Inc. director Carol Burt received an award of 1,073 Restricted Stock Units, vesting by November 2026.

Summary

• Carol Burt, a director of ResMed Inc. (RMD), was awarded 1,073 Restricted Stock Units (RSUs).
• The transaction date for this award was November 20, 2025.
• The RSUs were acquired at a price of $0, which is typical for RSU grants.
• Following this transaction, Carol Burt directly beneficially owns 2,156 shares of ResMed Common Stock.
• Additionally, 16,660 shares are indirectly beneficially owned through the Carol Burt Hilliard Trust.
• The RSUs will vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Sentiment

Score: 7

Explanation: The filing reports a routine equity award to a director, which is a positive for aligning interests but does not indicate significant new operational or financial news. It's a standard governance item.

Positives

• The award of Restricted Stock Units to Director Carol Burt aligns her interests with those of shareholders, incentivizing long-term performance.
• RSU grants are a common form of non-cash compensation for directors, reflecting standard corporate governance practices.

Future Outlook

The awarded Restricted Stock Units are scheduled to vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date, indicating a future equity event.

Industry Context

The grant of Restricted Stock Units to a director is a standard practice in the medical device and broader corporate sectors for executive and director compensation, aiming to align leadership incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a widely accepted practice across various industries, including healthcare and technology, similar to companies like Medtronic (MDT) or Stryker (SYK) which also utilize equity-based awards to incentivize their board members.
• The vesting schedule, tied to a future date or the next annual meeting, is typical for such awards, ensuring continued commitment from the director.

Stakeholder Impact

• Shareholders: The RSU award aligns the director's interests with long-term shareholder value, potentially leading to better governance and strategic decisions.

Next Steps

• The 1,073 Restricted Stock Units will vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation award to an existing director. While it aligns management interests with shareholders, it does not present new material information that would warrant a change in investment recommendation. The company's fundamental outlook remains unchanged based solely on this filing.

Keywords

ResMed, RMD, Carol Burt, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Form 4, Equity Award